China & Novartis
5 shared events · Importance 3 · Last updated Sep 22, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
China: Named alongside the United States as a rival attracting billions more in pharmaceutical investment, with spending at about 1.8% of GDP. Its rise adds pressure on Europe to reform its drug industry policies.
Novartis: A signatory of the open letter urging the European Union and member states to strengthen the region's pharmaceutical industry. The appeal is aimed at improving the investment and regulatory climate it operates in.
Sep 22, 2026 · 6 articles
Business
China: Home country of BoomRay, headquartered in Suzhou; the cross-border licensing deal highlights Chinese biotech innovation being licensed to a global pharmaceutical company.
Novartis: Licensee acquiring exclusive global rights to the RLT asset; expands its radioligand therapy portfolio and oncology pipeline with external innovation at limited upfront cost.
Sep 22, 2026 · 6 articles
Business
China: China's prolonged economic slump has weighed on the global luxury industry, contributing to LVMH's declining market value.
Novartis: Novartis is among the Swiss pharmaceutical giants that now dwarf LVMH in market value.
Sep 15, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how China and Novartis interact across events, view sentiment trends, and discover connected entities.
Open Dashboard